Cargando…

Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria

In this study, we evaluated Cu(L1) in two xenografted tumor-bearing (U87MG and MDA-MB-435) animal models to prove the concept that Cu(II)-labeled rhodamine derivatives, Cu(L) (L = L1 - L4) are useful as selective fluorescent probes for tumor imaging. We found that both multidrug resistance (MDR) neg...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xin, Zhou, Yang, Liu, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493204/
https://www.ncbi.nlm.nih.gov/pubmed/23139726
http://dx.doi.org/10.7150/thno.4818
_version_ 1782249220178182144
author Yan, Xin
Zhou, Yang
Liu, Shuang
author_facet Yan, Xin
Zhou, Yang
Liu, Shuang
author_sort Yan, Xin
collection PubMed
description In this study, we evaluated Cu(L1) in two xenografted tumor-bearing (U87MG and MDA-MB-435) animal models to prove the concept that Cu(II)-labeled rhodamine derivatives, Cu(L) (L = L1 - L4) are useful as selective fluorescent probes for tumor imaging. We found that both multidrug resistance (MDR) negative U87MG gliomas and MDR-positive MDA-MB-435 breast tumors could be visualized. Because of tissue attenuation, accurate quantification of tumor uptake was difficult by optical methods. Therefore, (64)Cu(L) (L = L1 - L4) were evaluated to compare their biodistribution properties. It was found that all four (64)Cu radiotracers had a high glioma uptake ((64)Cu(L1): 5.71± 1.43 %ID/g; (64)Cu(L2): 5.98 ± 2.75 %ID/g; (64)Cu(L3): 4.28 ± 1.45 %ID/g; and (64)Cu(L4): 6.25 ± 3.42 %ID/g) with (64)Cu(L1) showing the highest tumor/background ratios. In athymic nude mice bearing MDA-MB-435 breast cancer xenografts, (64)Cu(L4) showed almost identical normal organ uptake to that in the glioma-bearing animals, but its breast tumor uptake (1.26 ± 0.10% ID/g) was significantly lower (p < 0.001) than that in the glioma (6.25 ± 3.42% ID/g) because of MDR Pgps (P-glycoproteins) and MRPs (multidrug resistance-associated proteins) overexpressed in the xenografted MDA-MB-435 breast tumors. Results from cellular staining assays showed that both Cu(L2) and Cu(L4) were able to localize in mitochondria of U87MG cells, and their tumor selectivity was caused by the elevated negative mitochondrial potential in U87MG glioma cells as compared to that in human fibroblast cells. On the basis of these results, it was concluded that Cu(L) (L = L1 - L4) are useful as selective fluorescent probes for cellular staining assays and optical tumor imaging while (64)Cu(L) (L = L1 - L4) have the potential as PET radiotracers for tumor imaging. This study represents a good example of dual modality imaging (PET and optical) using two agents, (64)Cu(L) and Cu(L), with identical chemical composition. Future research will focus on developing new fluorescent probes with longer wavelength and reduced liver uptake.
format Online
Article
Text
id pubmed-3493204
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-34932042012-11-08 Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria Yan, Xin Zhou, Yang Liu, Shuang Theranostics Research Paper In this study, we evaluated Cu(L1) in two xenografted tumor-bearing (U87MG and MDA-MB-435) animal models to prove the concept that Cu(II)-labeled rhodamine derivatives, Cu(L) (L = L1 - L4) are useful as selective fluorescent probes for tumor imaging. We found that both multidrug resistance (MDR) negative U87MG gliomas and MDR-positive MDA-MB-435 breast tumors could be visualized. Because of tissue attenuation, accurate quantification of tumor uptake was difficult by optical methods. Therefore, (64)Cu(L) (L = L1 - L4) were evaluated to compare their biodistribution properties. It was found that all four (64)Cu radiotracers had a high glioma uptake ((64)Cu(L1): 5.71± 1.43 %ID/g; (64)Cu(L2): 5.98 ± 2.75 %ID/g; (64)Cu(L3): 4.28 ± 1.45 %ID/g; and (64)Cu(L4): 6.25 ± 3.42 %ID/g) with (64)Cu(L1) showing the highest tumor/background ratios. In athymic nude mice bearing MDA-MB-435 breast cancer xenografts, (64)Cu(L4) showed almost identical normal organ uptake to that in the glioma-bearing animals, but its breast tumor uptake (1.26 ± 0.10% ID/g) was significantly lower (p < 0.001) than that in the glioma (6.25 ± 3.42% ID/g) because of MDR Pgps (P-glycoproteins) and MRPs (multidrug resistance-associated proteins) overexpressed in the xenografted MDA-MB-435 breast tumors. Results from cellular staining assays showed that both Cu(L2) and Cu(L4) were able to localize in mitochondria of U87MG cells, and their tumor selectivity was caused by the elevated negative mitochondrial potential in U87MG glioma cells as compared to that in human fibroblast cells. On the basis of these results, it was concluded that Cu(L) (L = L1 - L4) are useful as selective fluorescent probes for cellular staining assays and optical tumor imaging while (64)Cu(L) (L = L1 - L4) have the potential as PET radiotracers for tumor imaging. This study represents a good example of dual modality imaging (PET and optical) using two agents, (64)Cu(L) and Cu(L), with identical chemical composition. Future research will focus on developing new fluorescent probes with longer wavelength and reduced liver uptake. Ivyspring International Publisher 2012-10-13 /pmc/articles/PMC3493204/ /pubmed/23139726 http://dx.doi.org/10.7150/thno.4818 Text en . This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Research Paper
Yan, Xin
Zhou, Yang
Liu, Shuang
Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria
title Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria
title_full Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria
title_fullStr Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria
title_full_unstemmed Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria
title_short Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria
title_sort optical imaging of tumors with copper-labeled rhodamine derivatives by targeting mitochondria
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493204/
https://www.ncbi.nlm.nih.gov/pubmed/23139726
http://dx.doi.org/10.7150/thno.4818
work_keys_str_mv AT yanxin opticalimagingoftumorswithcopperlabeledrhodaminederivativesbytargetingmitochondria
AT zhouyang opticalimagingoftumorswithcopperlabeledrhodaminederivativesbytargetingmitochondria
AT liushuang opticalimagingoftumorswithcopperlabeledrhodaminederivativesbytargetingmitochondria